Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA−24 with Tumor-Selective Toxicity
Pharmaceuticals · 23.02.2024 · 17 (3) · 291
DOI: 10.3390/ph17030291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 23.02.2024. Verfasst von Nannan Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science & Technology, China Pharmaceutical University, Nanjing 211198, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Breast cancer is a commonly diagnosed cancer worldwide. Human MutT homolog 1 (MTH1) is found to be elevated in breast tumors and cancer cells need MTH1 for survival. Pharmacological inhibition of MTH1 may be potentially beneficial in the treatment of breast cancer.
Methods
MA−24 was screened by malachite green colorimetric assay for MTH1 inhibitors and the kinetic characteristics of MA−24 were assessed. The features of MA−24’s binding with MTH1 were ascertained through molecular docking, and the cytotoxic activity of MA−24 was validated in vitro and in vivo. Target engagement assays, comet assay, and Western blot confirmed the intracellular target and mechanism of MA−24.
Results
MA−24 shows potent antitumor bioactivity both in vitro and in vivo. MA−24 competitively inhibited the MTH1 and further induced DNA strand breaks, leading to increased apoptosis of cancer cells depending on the upregulation of the cleaved-caspase 3–cleaved-PARP axis. In particular, MA−24 exhibited a powerful efficacy and safety in vivo (tumor growth inhibition rate: 61.8%).
Conclusions
MA−24 possesses a broad spectrum of breast cancer cytotoxicity and offered valuable insights for overcoming the challenges of chemotherapy-related toxicity, which holds great potential for the further development MA−24 as an anti-cancer drug.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Science & Technology, China Pharmaceutical University, Nanjing 211198, China.
- Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China.
ORCID-Profile: Nannan Kang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Kang, N., Ma, J., Hu, Y., Di, R., Wang, L., Zhang, X., Lai, Y., & Liu, Y. (2024). Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA−24 with Tumor-Selective Toxicity. Pharmaceuticals, 17(3), 291. https://doi.org/10.3390/ph17030291
Vancouver
Kang N, Ma J, Hu Y, Di R, Wang L, Zhang X, et al. Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA−24 with Tumor-Selective Toxicity. Pharmaceuticals. 2024;17(3):291. doi:10.3390/ph17030291
BibTeX
@article{Kang2024,
author = {Kang, Nannan and Ma, Jun and Hu, Yuling and Di, Rongrong and Wang, Lei and Zhang, Xuanling and Lai, Yisheng and Liu, Yu},
title = {Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA−24 with Tumor-Selective Toxicity},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {3},
pages = {291},
doi = {10.3390/ph17030291}
}
EUVIMED